A PDE Model for Imatinib-Treated Chronic Myelogenous Leukemia
暂无分享,去创建一个
Doron Levy | Peter S Kim | D. Levy | P. Kim | Peter P. Lee | Peter P Lee
[1] Dominik Wodarz,et al. Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[2] I. Glauche,et al. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses , 2007, Journal of Molecular Medicine.
[3] Doron Levy,et al. Modeling Imatinib-Treated Chronic Myelogenous Leukemia: Reducing the Complexity of Agent-Based Models , 2008, Bulletin of mathematical biology.
[4] A multiplicity result for a class of superquadratic Hamiltonian systems , 2003 .
[5] T. Holyoake,et al. Evolution of bone marrow transplantation--the original immunotherapy. , 2001, Trends in immunology.
[6] A. Fokas,et al. Mathematical model of granulocytopoiesis and chronic myelogenous leukemia. , 1991, Cancer research.
[7] Michael C Mackey,et al. A mathematical model of hematopoiesis--I. Periodic chronic myelogenous leukemia. , 2005, Journal of theoretical biology.
[8] Doron Levy,et al. Post-transplantation dynamics of the immune response to chronic myelogenous leukemia. , 2005, Journal of theoretical biology.
[9] Laurent Pujo-Menjouet,et al. Contribution to the study of periodic chronic myelogenous leukemia. , 2004, Comptes rendus biologies.
[10] Martin A. Nowak,et al. Dynamics of chronic myeloid leukaemia , 2005, Nature.
[11] Brent Neiman,et al. A Mathematical Model of Chronic Myelogenous Leukemia , 2000 .
[12] Helen Moore,et al. A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. , 2004, Journal of theoretical biology.
[13] SFT Thijsen,et al. Chronic myeloid leukemia from basics to bedside , 1999, Leukemia.
[14] Laurent Pujo-Menjouet,et al. A mathematical model describing cellular division with a proliferating phase duration depending on the maturity of cells. , 2003 .
[15] B. Druker,et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.
[16] F. Michor,et al. Mathematical models of targeted cancer therapy , 2006, British Journal of Cancer.
[17] Ingo Roeder,et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.
[18] Doron Levy,et al. Mini-Transplants for Chronic Myelogenous Leukemia: A Modeling Perspective , 2007 .
[19] Franziska Michor,et al. Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.